Chemokine-ligands/receptors: multiplayers in traumatic spinal cord injury.

Friederike Knerlich-Lukoschus, Janka Held-Feindt
Author Information
  1. Friederike Knerlich-Lukoschus: Department of Neurosurgery, University Medical Center Schleswig-Holstein, Arnold-Heller-Strasse 3, Haus 41, 24105 Kiel, Germany.
  2. Janka Held-Feindt: Department of Neurosurgery, University Medical Center Schleswig-Holstein, Arnold-Heller-Strasse 3, Haus 41, 24105 Kiel, Germany.

Abstract

Spinal cord injury (SCI) results in complex posttraumatic sequelae affecting the whole neuraxis. Due to its involvement in varied neuromodulatory processes, the chemokine-ligand/receptor-network is a key element of secondary lesion cascades induced by SCI. This review will provide a synopsis of chemokine-ligand/receptor-expression along the whole neuraxis after traumatic spinal cord (sc) insults on basis of recent in vivo and in vitro findings in a SCI paradigm of thoracic force-defined impact lesions (Infinite Horizon Impactor) in adult rats. Analyses of chemokine-ligand/receptor-expression at defined time points after sc lesion of different severity grades or sham operation revealed that these inflammatory mediators are induced in distinct anatomical sc regions and in thalamic nuclei, periaqueductal grey, and hippocampal structures in the brain. Cellular and anatomical expression profiles together with colocalization/expression of neural stem/progenitor cell markers in adult sc stem cells niches or with pain-related receptors and mediators in dorsal horns, dorsal columns, and pain-processing brain areas support the notion that chemokines are involved in distinct cascades underlying clinical posttraumatic impairments and syndromes. These aspects and their implication in concepts of tailored SCI treatment are reviewed in the context of the recent literature on chemokine-ligand/receptor involvement in complex secondary lesion cascades.

References

  1. Brain. 2006 Oct;129(Pt 10):2761-72 [PMID: 16825202]
  2. J Neurosci. 2009 May 27;29(21):6945-54 [PMID: 19474321]
  3. Trends Immunol. 2005 Oct;26(10):529-34 [PMID: 16099720]
  4. Nat Rev Neurosci. 2008 Jun;9(6):481-93 [PMID: 18490917]
  5. J Neurosci Res. 2015 Apr;93(4):562-71 [PMID: 25491360]
  6. Arch Phys Med Rehabil. 2015 Apr;96(4):633-44 [PMID: 25461821]
  7. Trends Pharmacol Sci. 1999 Feb;20(2):73-8 [PMID: 10101968]
  8. Arch Phys Med Rehabil. 2007 May;88(5):638-45 [PMID: 17466734]
  9. Brain Res Brain Res Rev. 2005 Feb;48(1):16-42 [PMID: 15708626]
  10. J Neurosci Res. 1998 Aug 1;53(3):368-76 [PMID: 9698165]
  11. Prog Brain Res. 2009;175:125-37 [PMID: 19660652]
  12. Glia. 2006 Oct;54(5):471-83 [PMID: 16886211]
  13. J Biol Chem. 1996 Feb 23;271(8):3975-8 [PMID: 8626727]
  14. J Neurosci. 2007 Aug 15;27(33):8893-902 [PMID: 17699671]
  15. J Comp Neurol. 2005 Nov 14;492(2):178-92 [PMID: 16196033]
  16. Neurochem Int. 2000 Apr;36(4-5):417-25 [PMID: 10733009]
  17. J Neurotrauma. 2003 Feb;20(2):179-93 [PMID: 12675971]
  18. Glia. 2010 Jun;58(8):916-31 [PMID: 20155816]
  19. J Anat. 2005 Sep;207(3):241-50 [PMID: 16185248]
  20. Nat Rev Neurosci. 2003 Jun;4(6):444-55 [PMID: 12778117]
  21. Exp Neurol. 2006 Jan;197(1):177-88 [PMID: 16266704]
  22. Eur J Pharmacol. 2008 Sep 11;592(1-3):93-5 [PMID: 18656466]
  23. J Neurosci Res. 2007 Aug 15;85(11):2422-32 [PMID: 17567884]
  24. Exp Neurol. 2008 Feb;209(2):294-301 [PMID: 17617407]
  25. Chin J Traumatol. 2005 Aug;8(4):216-9 [PMID: 16042867]
  26. Eur J Neurosci. 2004 Sep;20(5):1150-60 [PMID: 15341587]
  27. J Neurosci. 2000 Mar 15;20(6):2218-28 [PMID: 10704497]
  28. Arch Phys Med Rehabil. 2007 Nov;88(11):1384-93 [PMID: 17964877]
  29. J Pharmacol Sci. 2010;114(4):347-53 [PMID: 21081837]
  30. J Neurosci Res. 2001 Jun 15;64(6):582-9 [PMID: 11398181]
  31. J Immunol. 2004 Jul 1;173(1):594-9 [PMID: 15210821]
  32. Pain. 2012 Sep;153(9):1916-31 [PMID: 22789131]
  33. J Neurosci. 1996 Dec 1;16(23):7599-609 [PMID: 8922416]
  34. Clin Neurosci Res. 2006 Dec;6(5):283-292 [PMID: 18059979]
  35. Glia. 2006 Jan 1;53(1):81-91 [PMID: 16206198]
  36. J Neurosci Res. 2004 Apr 1;76(1):20-34 [PMID: 15048927]
  37. J Neurotrauma. 2008 May;25(5):427-48 [PMID: 18338959]
  38. J Neurochem. 2005 Apr;93(2):452-62 [PMID: 15816868]
  39. Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10655-60 [PMID: 17551020]
  40. Prog Neurobiol. 2007 Sep;83(1):2-23 [PMID: 17580100]
  41. Front Cell Neurosci. 2014 May 28;8:154 [PMID: 24920943]
  42. Exp Neurol. 2005 Jun;193(2):394-410 [PMID: 15869942]
  43. J Comp Neurol. 1972 May;145(1):61-83 [PMID: 4624784]
  44. Ann N Y Acad Sci. 2002 Jun;961:346-9 [PMID: 12081936]
  45. Glia. 2003 Apr 15;42(2):172-83 [PMID: 12655601]
  46. J Neurotrauma. 2011 Apr;28(4):619-34 [PMID: 21265596]
  47. Exp Neurol. 2001 Nov;172(1):115-27 [PMID: 11681845]
  48. J Pharmacol Exp Ther. 2008 May;325(2):641-5 [PMID: 18281594]
  49. Brain Behav Immun. 2010 May;24(4):540-53 [PMID: 19932745]
  50. Neurosci Lett. 2008 May 30;437(2):98-102 [PMID: 18448252]
  51. Curr Pharm Des. 2005;11(10):1223-36 [PMID: 15853679]
  52. Neuroscience. 2008 Nov 19;157(2):446-52 [PMID: 18822355]
  53. Neuroscientist. 2007 Apr;13(2):173-85 [PMID: 17404377]
  54. Exp Neurol. 2008 Feb;209(2):378-88 [PMID: 17662717]
  55. Arch Phys Med Rehabil. 2013 Aug;94(8):1498-507 [PMID: 23618747]
  56. Brain Res Rev. 2009 Apr;60(1):125-34 [PMID: 19146875]
  57. Methods Mol Biol. 2006;332:3-49 [PMID: 16878684]
  58. Brain Behav Immun. 2010 Aug;24(6):859-65 [PMID: 20347955]
  59. J Inherit Metab Dis. 2013 May;36(3):455-66 [PMID: 23344887]
  60. Curr Opin Anaesthesiol. 2008 Oct;21(5):580-5 [PMID: 18784482]
  61. J Pain Res. 2013 Nov 21;6:803-14 [PMID: 24294006]
  62. Neurochem Int. 2013 Nov;63(5):363-7 [PMID: 23927862]
  63. Cell Death Differ. 2006 Mar;13(3):534-6 [PMID: 16410798]
  64. J Neurotrauma. 2014 Sep 15;31(18):1561-9 [PMID: 24786364]
  65. Pharmacol Ther. 2010 Apr;126(1):56-68 [PMID: 20117131]
  66. Eur J Neurosci. 1997 Dec;9(12):2549-60 [PMID: 9517460]
  67. J Neurotrauma. 2010 Apr;27(4):669-82 [PMID: 20038240]
  68. Cell. 2002 Aug 9;110(3):373-83 [PMID: 12176324]
  69. Exp Neurol. 2014 Aug;258:105-11 [PMID: 25017891]
  70. Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4536-41 [PMID: 15764707]
  71. Brain. 2014 Aug;137(Pt 8):2193-209 [PMID: 24919967]
  72. J Leukoc Biol. 2005 Dec;78(6):1204-9 [PMID: 16204637]
  73. Neurosurg Focus. 2008;25(5):E2 [PMID: 18980476]
  74. Clin Epidemiol. 2014 Sep 23;6:309-31 [PMID: 25278785]
  75. Eur J Pharmacol. 2001 Oct 19;429(1-3):115-9 [PMID: 11698032]
  76. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10276-81 [PMID: 12130663]
  77. Glia. 2005 May;50(3):258-69 [PMID: 15756692]
  78. J Neurosurg Spine. 2011 May;14(5):583-97 [PMID: 21332278]
  79. Drug Alcohol Depend. 2007 Apr 17;88(1):36-41 [PMID: 17049756]
  80. Glia. 2003 Jul;43(1):37-43 [PMID: 12761864]
  81. Trends Neurosci. 1999 Nov;22(11):504-12 [PMID: 10529818]

MeSH Term

Animals
Chemokines
Disease Models, Animal
Humans
Receptors, Chemokine
Spinal Cord Injuries

Chemicals

Chemokines
Receptors, Chemokine

Word Cloud

Created with Highcharts 10.0.0SCIsccordlesioncascadesinjurycomplexposttraumaticwholeneuraxisinvolvementsecondaryinducedchemokine-ligand/receptor-expressiontraumaticspinalrecentadultmediatorsdistinctanatomicalbraindorsalSpinalresultssequelaeaffectingDuevariedneuromodulatoryprocesseschemokine-ligand/receptor-networkkeyelementreviewwillprovidesynopsisalonginsultsbasisvivovitrofindingsparadigmthoracicforce-definedimpactlesionsInfiniteHorizonImpactorratsAnalysesdefinedtimepointsdifferentseveritygradesshamoperationrevealedinflammatoryregionsthalamicnucleiperiaqueductalgreyhippocampalstructuresCellularexpressionprofilestogethercolocalization/expressionneuralstem/progenitorcellmarkersstemcellsnichespain-relatedreceptorshornscolumnspain-processingareassupportnotionchemokinesinvolvedunderlyingclinicalimpairmentssyndromesaspectsimplicationconceptstailoredtreatmentreviewedcontextliteraturechemokine-ligand/receptorChemokine-ligands/receptors:multiplayers

Similar Articles

Cited By